market perform
reason report
op
bottom line upgrad share outperform
believ sever long-term overhang lift includ
stabil gener brand price
perspect less risk drug price reform believ
less threat mani investor expect regard
futur growth believ red oak give access
best rate market enabl win share
op optum growth rate like acceler y/i
basi encourag pharma result
well ahead expect within medic
encourag divis final deliv oper
margin near-term expect continu take share
mp believ patient recoveri busi
deliv accret given near
trough ntm price-to-earnings multipl improv fundament
upgrad stock outperform
brand gener price trend seem stabl rel
experi estim gener deflat price trend
stabl rel distribut manag team
indic gener deflat trend still challeng
price within guidanc rang beat buy-
side sell-sid price in-lin nadac im data confirm
gener brand price trend stabl
regulatori risk seem reduc believ less risk
around drug price reform council econom advis report
highlight sever polici initi administr could pursu
none seem overli burdensom distributor view
move part part may creat challeng suspect
actual implement sort program may harder
achiev mani expect item rebat flow reform
fda reform seem benign
risk also reduc cnbc recent publish articl
highlight shelv plan enter hospit
survey show like gain modest share
hospit medic distribut next year see link
view take medic distribut share
channel time howev view risk manag
net debt total capit
ep
compani inform leerink partner llc research
revenu present billion dollar
adj dilut ep continu oper
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rx trend deriv im health
incom beat estim consensu driver
beat larg perform red oak believ red oak
competit buy-sid rate market estim
buy scale greater believ
take share drug distribut side believ growth
optum acceler gener bio-similar launch
calendar also act tailwind manag guid signific
y/i declin pharma oper incom believ
overli conserv beat expect quarter
would expect sentiment shift posit
medic pois captur oper margin exclud
inventori step-up charg incur
medic oper incom would increas y/i
manag tout oper margin goal year
fulli expect achiev goal still expect
patient recoveri busi gener accret
believ sentiment like turn posit medic margin
upgrad outperform given reduc risk sever overhang
includ brand gener price trend regulatori price reform
posit stock also believ red oak
provid excel buy-sid rate believ optum
volum contribut good top-lin growth expect
take share within medic believ manag meet
long-await oper margin goal near-term upgrad
op increas pt
one largest pharmaceut distributor countri one
major cardin busi base pharmaceut distribut medical-
surgic suppli distribut ancillari support servic jv reli
redoak drug purchas consortium sourc pharmaceut product estim
redoak gener market share allow sourc product
competit rate serv pharmaci specialti pharmaci
suppli relationship hospit util level remain somewhat
depress industri believ done good job execut tuck-in
acquisit grow footprint faster grow market segment includ home health medic
surgic distribut includ recent acquisit medtron patient recoveri busi
cordi addit though sold distribut busi china compani retain
presenc help sourc higher margin prefer product add
cardin product portfolio believ manag highli compet like
cash-flow characterist busi provid abil leverag larg
fix cost infrastructur recent remov overhang concern amazon would
enter pharma suppli chain recent survey work show amazon like less
threat initi fear core medic distributor defend moat believ
sentiment improv gener brand drug price trend stabil
believ continu solid execut result time benefit
improv sentiment multipl expans current level result rate cardin
upgrad outperform
upgrad share mp op posit stock sever
reason includ remov sever stubborn long-term overhang weigh
sector group well posit medium-term growth driver view
overhang remov greatli diminish includ gener brand price
stabil rel cah experi believ less regulatori risk come
trump administr believ less threat come
term long-term growth potenti believ red oak give access
best price market enabl win share optum
grow benefit margin medic divis like reach near-term
pharma margin past quarter came well ahead expect gener launch
calendar seem favor cah balanc sheet cash flow seem solid stock
near trough price-to-earnings basi given remov set signific headwind trough
valuat posit earn outlook upgrad stock outperform
risk reward profil far favor
trail distributor peer past year believ
stabil drug price trend conjunct better-than-expect sourc red oak
provid potenti expand margin view recent report cnbc
claim amazon shelv plan enter pharmaceut suppli chain hospit
like clear event lead better sentiment stock group combin
recent survey work continu believ fear surround amazon entranc
medic suppli distribut market larg over-don believ amazon
slowli gain modest amount share next five year current trade
signific discount histor valuat ntm price-to-earnings basi ntm p/fcf trade near
trough rel peer current trade larger discount ntm price-to-earnings basi
consid compani strong posit new leadership ceo mike kaufman remov
amazon overhang compar attract valuat see upsid share
sentiment turn posit new one year price target base trade
ep estim
stabil brand gener price rel cah
rel cah expect gener deflat still headwind stabl
brand price appear in-lin expect gener deflat serv larg
driver pharma segment oper margin compress view recent stabil
gener deflat rate lead indic increas segment profit gener
deflat reach lower level deflat rate appear stabil sinc
gener price trend larg consist manag guidanc januari
investor confer mike kaufman cfo told investor steep curv
term amount re-pric see specif gener seem
lessen saw first half thing seem get normal
histor standard commentari conjunct forecast mid-singl digit price
deflat sell-sid larg appear consist gener drug trend calcul
reason gener deflat rate appear trend rang
differ mid-single-digit rang nadac data equal weight
amongst product includ discount mix differ
import distinct rel appear stabil
brand-price-infl seem trend in-lin guidanc regard brand
drug price trend appear consist manag guidanc manag
consist guid brand inflat in-lin calcul price
trend manag describ stabil trend evidenc chart
exhibit spike januari consist annual price increas
chart show analysi brand inflat sale weight basi use im
data brand price deceler significantli y/i growth y/i
growth trend line line cah guidanc call brand
pharmaceut distributor guidanc point stabil
price trend
big distributor present investor confer januari three
manag team provid commentari around price trend larg reiter
recent earn call show manag guidanc price compar
estim actual price base nadac data see price brand
consist compani guidanc bit better mck guidanc gener side
believ deflat high end guidanc rang although appear stabil
wake increas gener anda applic manufactur look
exit line busi op fourth-largest gener
manufactur vocal headwind face manufactur
produc gener drug product gener deflat continu estim endo gener
divis stop manufactur sever product ceo paul campanelli
recent quot bloomberg articl say alreadi year request six
differ product make answer even could price
still low wouldnt abl bring back product
recent investor confer teva cfo michael mcclellan describ convers
manufactur buyer
convers pretti simpl guy prepar continu lose
money fine want go supplier
abl press price competit bid either need
someth sustain us walk away expect
probabl lot busi move produc
abl produc volum meet price custom
similar sentiment express paul bisaro presid ceo ipxl
op compani earn call respect product ration
talk less dozen product ration compani
continu evalu portfolio regularli turn product either viabl
us whether cost whatev ration exit amidst
continu gener deflat manufactur voic complaint ration
portfolio trend believ like continu fda continu work speed
market new drug approv brand drug project loe next five
amazon may shelv pharma distribut ambit april cnbc
report link amazon shelv pharma distribut plan instead focus
effort sell less sensit medic suppli hospit smaller clinic consist
previous publish work link link view help remov
substanti overhang distributor seen multipl compress
stock price pull-in fear amazon would enter pharma suppli chain view
report suggest amazon unlik enter pharma suppli chain within next two
year howev total rule entri amazon futur spoke
medacorp kol formerli serv senior execut amazon member jeff
bezo senior leadership team kol highlight amazon hold annual seri
meet assess whether enter scale certain product categori link
small team typic task market research explor effort even
formal decis made enter market small team continu work
potenti entranc continu believ healthcar pharma market requir
signific sophist continu deter entranc amazon near-term
appear amazon find suppli distribut challeng big three pharma
distributor medic suppli exposur mean dual
threat howev cnbc articl suggest amazon found suppli distribut
challeng compani expect found hard alter buy habit
healthcar institut cite two peopl familiar cnbc report amazon struggl
land contract larg hospit network despit conven advisori board includ
major hospit execut ultim cnbc articl conclud sever physician
interview cnbc said stick exist distributor suppli
reli amazon item emerg consist found
convers kol recent survey
conduct medacorp survey medic suppli distributor link focus
medical-surg suppli chain shed light amazon viabil distributor proprietari
survey medacorp specialist captur data respond dental practic veterinari
practic hospit physician group practic overal found amazon remain
threat like gain share exist distributor next year threat like
larg recent price movement suggest rather amazon appear pois captur
market share certain product appear like amazon becom primari
distributor major survey respond also notabl survey
like lose share share loss estim survey much smaller
believ price stock also appear element sticki
loyalti medical-surg suppli chain make switch distributor unlik
scenario mani provid
survey result suggest could face minim share loss period
ask survey respond percent suppli current purchas varieti
tradit distributor medical-surg veterinari space includ list
amazon also ask respond contrast percentag purchas
expect direct toward distributor year well repres
survey respond current direct spend toward compani
appear next year compani could stand lose much current
suppli spend view basi point market share period
hospit major custom respond survey show slightli
share loss potenti physician group practic howev number still remain small
respect geograph basi appear metropolitan-bas
provid like reduc purchas
distributornowin yearsnowin yearsnowin yearsnowin yearsnowin percent suppli current purchas follow distributor percent suppli expect purchas themin year group practiceveterinari practicehospitaldent practic inc
amazon unlik becom primari distributor base feedback survey
respond amazon expect gain believ modest percentag suppli
spend five year appear like amazon would becom primari distributor
ask survey respond whether believ amazon could becom primari
distributor respond said
substanti price discount requir win signific share one interest
takeaway survey respond claim price import factor
distribut relationship select new distributor appear substanti
price discount would requir respond switch distributor total appear like
provid would need discount price switch distributor
practic areacurr spendfutur spendchangecount current group settingrur percent organ total suppli purchas includ medic devic expect purchas year cardin inc
provid good price hospit ask survey respond rate
distributor price rate repres least expens distributor regard
hospit got score slightli view
show rel mainstream distributor actual competit price
much increment discount would take switch distributor discount neededtot hospit physician group practic dental practic veterinari practicesselect commentsw choos trust cost issu safeti trust right biggest reason chang less money servic bad servic cost problem would make convers worth requir price similar distributor similar servic would take switch amazon qualiti concern current provid would need justifi switch cost would vari base exclus term even small discount similiar qualiti good multipli million save two hospit local network hundr nationwidechang order pattern cost lower cost need off-set increas cost oper current get excel servic deliveri time per weekth current distributor know system equip would take big discount switch feel like held hostag feel would take signific discount replac experienc better custom servic current distributorit money realli suppli side make sure product deliv time worthwhil disrupt patterni would need know qualiti custom care thereth discount must signific enough risk disrupt suppli possibl inferior qualiti goods/substitut supplier base availabilitymi comfort level valuabl well individu attent tlc grow long-stand local relationshipspric import qualiti importantwould big discount movetot averag discount would rate distributor term price internationalpdcomwi anim healthothercah group inc
score better qualiti price similar price rank survey respond
rate distributor qualiti scale earn neg
surpris see rank behind sinc doesnt even major
hospit distribut busi take share past year
view risk signific market alter drug price reform reduc presid
donald trump expect deliv speech april may cover signific aspect
drug price reform may surpris speech believ mani
polici trump may cover alreadi outlin highlight council
econom advis report publish februari sever item includ
report reform medicaid best price account overal health member
period time reform part price reduc asp rate and/or potenti move
program part caus rebat flow directli member part
increas gener drug competit creat competit pbm industri chang
negoti tactic foreign govern reform fda reform price
variou reform polici one would drive unfavor impact
distributor view would part reform typic distributor ship specialti
product clinic physician offic reimburs rate doctor receiv
medicar impact view rate will pay
distributor servic provid part rate declin shift part
distributor could get squeez
risk type reform could occur posit surpris learn
leerink healthcar servic roundtabl medacorp specialist medpac believ
could difficult actual implement transit concern highlight
specialist temperatur control issu certain product methodolog could
use get specialti product member physician possibl challeng relat
treatment within part program believ member receiv treatment quickli
sick patient receiv care rapid manner specialti product start flow
prescript drug benefit could potenti delay treatment could
possibl impact qualiti timeli care deliv result senior execut
would rate distributor term qualiti qualiti internationalpdcomwi anim healthothercah group inc
medpac seem skeptic abil desir move part part even part
 margin client deterior bp estim maximum exposur
would
possibl reform area seem like would overli materi neg
impact cah oper earn new definit medicaid best price could drive
consult servic demand rebat flow directli member may actual increas
number prescript taken member
pharma seem turn corner
cardin pharma oper incom come signific pressur due mainli gener
deflat loss safeway invest technolog solut year
guid low doubl digit declin pharma oper incom y/i basi headwind
includ gener deflat invest technolog platform sale china
busi invest client challeng
post y/i declin pharma oper incom well ahead expect
guidanc manag highlight pharma beat driven mainli better
expect perform red oak pharma segment revenu grown steadi pace
estim divis grow revenu annual pace
expect cah oper margin becom resili time would expect see
growth expans gener deflat rate stabil loss safeway lap
loss china modest headwind cash receiv use pay
debt repurchas stock cah oper margin face signific compress respons
gener deflat oper margin segment peak
finish forecast segment oper margin stabil
lower margin rate larg consensu expect view
compress cah pharma segment oper margin led declin gener
drug deflat accord calcul nadac drug price data declin
averag rate averag rate
exposur shift part drug part program mm abcmckcahpart market part margin tax inc
redoak sourc may provid abil
improv margin pharma segment
redoak one three larg drug purchas consortium emerg amid continu
consolid partnership pharma suppli chain consolid pharma suppli
chain result three larg purchas consortium wbad claruson red oak
consortium larg form partnership joint ventur allow member
leverag power achiev better drug price view best buy
scale leverag market given ventur creat
walgreen respect estim red oak wbad gener
purchas market share believ consortium give advantag
buy sell side market accord puls call held
decemb link consortium may similar buy power market share
tend toward one anoth individu believ price close believ everi
price differenti materi commentari cah manag suggest
redoak outperform rel expect
better perform anticip cost side conjunct in-lin sell-sid
price suggest margin expand guid gener deflat in-lin
guidanc mid-singl digit deflat sell-sid manag told investor
earn call redoak sourc power help cost side help lead
strong perform pharma segment quarter
think good quarter segment absolut exceed
expect mention lot red oak
perform cost side piec mention that slightli
better help us cost side deflat track
expect cost track littl bit better that drive upsid us
deflat trend in-lin expect better expect perform cost-
side buy-sid manag effect hint abl drive margin
expans pharma segment pharma oper margin beat model
believ better-than-expect perform cost side allow continu
improv margin segment
data show win share
data tabl believ still relev data show
win new account distributor survey
believ win due price qualiti servic deliv especi
hospit
tabl show client believ give best price
market like explain cah retent rate high survey
addit potenti superior price model believ enabl win share
long-term also believ growth optum support cah top-lin growth
estim retail pharmaci busi actual shrank y/i basi
given increment volum win back believ growth
rate acceler mean may benefit
increment revenu likewis y/i top-lin growth rate optum past
quarter impress come y/i growth rate post optum
all-in estim increment pharmaceut revenu rang
rel given superior growth rate
optum estim could convert annual
win loss analysi survey respond loss base servic win hospit retailth loss loss hospit retailth one win due pharmaci win tbd rivet citi loss b/c retent rate seem said said said said said said may share donor due pricemi primari provid best rateprimaryhow would rank distributor price cost highest cost inc
success acquisit aet believ even prescript volum
would direct store would also drive revenu growth
success acquisit esrx believ could act modest headwind
current suppli optum suppli esrx howev consid
portion ci volum flow mail channel estim total unfavor
impact would revenu assum mail penetr rate
medic segment pois deliv oper margin
medic segment appear pois reach long-term goal oper margin goal
manag talk realiz oper margin medic divis
year segment oper profit impact unfavor inventori step-
charg exclud charg medic divis oper margin would
view key mileston medic segment oper incom
increas y/i would increas y/i exclud
inventori step-up charg headwind cordi on-going exam glove challeng continu
acquisit medtron patient recoveri busi complet juli
expect accret accret help
off-set exam glove challeng current model oper margin
optum impact analysistot revenu mm y/i y/i optum increas optum ep impact mm eincrement tax mm cardin inc
acquisit medtron patient recoveri busi bolster medic segment help
provid diversif growth
juli cardin complet acquisit
medtron patient recoveri busi
consist mdt patient
deep vein thrombosi
nutrit insuffici busi
suppli electrod needl syring
sharp dispos product line
busi tradit
report part mdt patient
collect refer patient recoveri busi compos portion
mdt overal patient monitor recoveri busi part compani minim
invas therapi group suffer sever quarter weak throughout
segment appear rebound report april year-end
acquisit complet mdt
announc acquisit roughli year ago april guid togeth
variou busi unit togeth account revenu twelv month
end octob revenu patient recoveri
busi provid strong portfolio manufactur medic product sold
multipl healthcar channel
acquisit expect meaning accret align well cah medic
offer manag guid time acquisit expect achiev least
patient monitor recoveri annual compani document leerink partner estim inc
accret adj ep includ inventori step-up increas
interest expens result new debt use fund deal manag guid
expect adj ep accret increasingli accret
thereaft well deal expect gener annual synergi exceed
view deal align well cah medic offer though compani
exceed tradit leverag ratio believ compani
success reach target lower debt/adj ebitda ratio
estim addit patient recoveri busi add sku across
product categori total sku across categori
view brand acquir well regard market help expand
offer along continuum care estim manufactur sourc
uniqu product across continuum care
commod headwind weigh medic segment
manufactur sourc varieti product within medic segment includ
surgic exam cleanroom glove medic glove though seemingli small part cah
larg busi present headwind manag size headwind
describ one two largest driver medic segment current medic glove
busi featur mani fix price contract time rise price pose headwind
manufactur varieti glove includ latex nitrile-bas glove howev larg portion
vinyl-bas glove compos polyvinyl chlorid pvc pvc price bottom
februari sinc bottom increas april year-to-d price
increas
commod item compani typic shift supplier help off-set price
headwind specif supplier region pvc howev china control major
market accord ih data growth pvc market come china
china account global capac concentr suppli pose
signific problem price china reli coal-bas acetylen product process
wherea major global product reli ethylen process on-going
concern pollut roll factori outag china common step reduc pollut
suppli vari littl warn result global capac util estim
hedg portion commod exposur sourc number commod
addit pvc includ oil-bas resin nitril cotton diesel fuel latex like
compani hedg portion exposur annual provid sampl
scenario test exposur given fluctuat commod price scenario
assum commod price collect shift direct custom price
abl shift respons exclud addit medtron patient recoveri busi
complet juli estim rang direct indirect commod
exposur tax basi estim
adjust ep estim ytd pvc rate increas would
foreign exchang hedg well compani global oper cardin expos
transact translat currenc associ risk tradit hedg
translat exposur hedg transact exposur june june
cardin hedg transact exposur currenc
cardin expos includ australian dollar canadian dollar chines renminbi
euro japanes yen mexican peso philippin peso russian rubl singapor dollar thai
baht cardin perform sensit analysi forecast currenc exposur annual
provid result estim fluctuat chart
increas transact exposur result cordi acquisit manag
expect increas due acquisit medtron patient recoveri busi
translat exposur also expect increas due acquisit chart
assum chang valu dollar rel foreign currenc
histor deliv steadi perform
despit numer headwind cardin abl deliv good earn
perform past year met beaten consensu ep estim
time meet beat consensu revenu ebitda estim
beaten time respect averag tend beat top line
bottom line believ solid track record combin
stabil price trend may provid durabl cah ntm price-to-earnings multipl drug
sourc trend better expect gener deflat stabil increment
posit cah abil deliv better-than-kaufman expect perform
mike kaufman promot ceo januari bring immens experi role
mr kaufman work cardin year previous serv cfo cfo
mr kaufman task overse global sourc pharmaceut medic
segment well financi activ opinion mr kaufman smart talent
execut bring signific drug purchas experi role help
compani continu deliv solid result despit continu gener deflat headwind given
recent promot like mr kaufman heavili incentiv show steadi result
believ transpar commun style posit routin made point
provid clear succinct explan lever corpor profit goe
way clearli explain often opaqu driver drug price exampl recent investor
confer januari mr kaufman gave follow explan ask rate
gener deflat compani experienc
defin gener deflat specif comment mid-
singl digit talk point-to-point averag sell price decreas
averag sell price gener june june
fy declin defin
averag sell price point point june june juli june
go go mid-singl digit exampl let say would
manufactur howev talk overal sell price go
cost think us maintain margin dollar rate
sinc cost lower sell go take cost
order cost make exampl simpl
sell averag cost averag begin
year go end year go go
maintain margin dollar would
manufactur cost actual think two reconcil
well base definit definit would concern
say go say
go actual problem mean
margin dollar thing equal squeez
realli import understand talk sell talk cost
cost go sell go see margin
dollar compress expect year
lengthi quotat mr kaufman explan clear explan question
complex market dynam usual given way believ attract type
investor name manag help make industri busi understand
approach
reduc guidanc twice kaufman leadership cfo believ
much due gener deflat trend perform cordi medic
divis re-invest back busi view gener price trend
stabil medic divis margin ahead expect last quarter believ
kaufman greater incent deliv result given ceo entir
organ pharma divis also beat expect due partli red oak sourc
capabl sell-sid stabil
reduct guidanc may impact investor confid manag
though hold ceo mike kaufman high regard appreci open transpar easi
follow messag style would remiss highlight manag lower
guidanc sever time earn call manag introduc guidanc
expect adj ep rang follow quarter guidanc reduc
lower manag
effect lower guidanc state result would toward low-end
guidanc rang previous issu ultim cah adj ep slightli
low-end guidanc rang gener deflat serv headwind
sever reduct guidanc may impact investor confid manag
manag disappoint sever cut singl digit percentag growth y/yhigh singl digit percentag growth y/ymid high singl digit percentag growth y/yadj bottom previou rang compani document leerink partner guidanc cardin health inc
loss exclus wave new gener tailwind pharma segment
estim segment repres cah revenu
lions-shar cah busi segment deriv major margin gener
drug product recent studi schaeffer center health polici econom
univers southern california usc found wholesal earn gross margin
gener compar brand drug product im project total
brand drug product lose exclus loe provid tailwind pharma
distributor interestingli project face loe next three year
biolog biolog loe project peak
conjunct on-going work fda link speed pace gener market
increas pace approv believ outlook portend signific tailwind
valuat attract
under-perform pharmaceut distribut peer
weak perform rel two pharma distributor past year
april close record cumul total return past
substanti trail abc total return mck total return chart
cah price perform denot blue line move similar fashion
distributor trail peer green yellow/orang substanti
valuat highlight abil gener seen multipl contract
significantli past year april trade high ntm price-to-earnings
 rel basi face sever headwind past year includ gener
deflat amazon concern conjunct recent enact tax reform cah
ntm price-to-earnings ratio declin current level shown chart
even though chart skew slightli due tax reform estim
posit tax benefit worth annual ep see even increas
ntm price-to-earnings stock would still trade well histor averag
ev/ebitda basi trade averag ev ebitda multipl
make appear slightli histor trade rang view metric
skew slightli recent incur signific debt medtron patient recoveri
rel peer trade discount ntm price-to-earnings equal peer group
averag howev averag skew substanti face signific multipl
compress ignor appear trade slightli higher discount histor
averag ntm price-to-earnings multipl ntm ev/ebitda basi actual trade modest
discount histor valuat compar peer may due debt load
incur medtron patient recoveri busi amongst group cheapest
free cash flow basi screen well rel histori rel peer
consensu estim peg free cash flow ntm basi trade
price free cash flow multipl well averag peer
trade higher except
cardin current trade margin trough price ntm free cash flow valuat
made low late trade ntm p/fcf trade
substanti discount five year averag
 year trade multiplescurrentavg discountmaxmincurrentavg factset p/entm year trade multiplescurrentavg factset price cardin health inc
cardin strong histori deliv exce net incom
impact part signific technolog invest made compani pharmaceut
platform complet project set rebound
estim deliv exce net incom
strong free cash flow gener allow continu return cash sharehold
option deploy capit select accret
upgrad outperform
upgrad share outperform believ sever overhang
remov stock includ brand gener price regulatori risk concern
posit side beat pharmaceut divis earn expect past
quarter due mainli red oak gener launch calendar appear favor us medic
divis pois meet exceed oper margin like align
optum two larg client gain share would expect benefit given
near trough valuat believ risk reward profil favor upgrad
stock outperform
stock trade ep estim histor
ntm price-to-earnings averag rel ep trade
trade next month expect share trade
ep would put stock use slightli higher
multipl valuat analysi due improv sentiment part due remov amazon
overhang new leadership ceo mike kaufman improv margin potenti
pharmaceut divis still face headwind medic segment
believ core busi perform well upgrad op
risk valuat
competit intens custom concentr high compet
op mp well sever smaller medical-
surgic distributor includ owen minor mp inc mp
result competit custom buy-sid sell-sid may constantli tri
pressur margin novat premier larg custom present renew risk
lose custom custom put signific margin pressur
compani earn could come pressur
price could declin reform also pose risk price brand-nam
drug gener declin time margin could come
pressur addit patient protect afford act health
educ reconcili act implement signific chang industri exampl
increas rebat paid manufactur fee must paid could advers
impact buy-sid margin abl earn addit retail pharmaci
face margin pressur due chang medicaid reimburs chang
awp could pressur compani sell-sid margin
regul extens drug distribut busi subject extens law
regul cover mani aspect compani oper includ fraud
abus law prescript drug pedigre track mani requir mandat
fda state feder law agenc compani requir
hold licens permit oper distribut center
tax posit pose risk oper mani state throughout
world tax law complex within intern perspect
addit ever refin lifo account could advers impact
inform system compani reli inform system within corpor offic
throughout distribut center technolog system complex requir
facilit purchas distribut thousand inventori line-item receiv process
ship order manag bill collect process payment mani function
reason technolog system fail function properli cardin
acquisit integr could risk perform fair number
acquisit past sever year may continu acquir futur
compani fail integr acquisit onto platform inform
technolog personnel structur issu integr process compani
earn could risk
concentr supplier pose risk supplier make
revenu five supplier gener compani busi contract typic
written one-year basi automat renew year five year given somewhat
high degre concentr among manufactur depend
honor supplier agreement relationship end deterior
manufactur put price pressur compani earn could
risk addit depend raw materi commod includ
nuclear materi price oil impact distribut transport cost
econom trend compani global oper impact econom trend
exampl recess could caus patient less will go physician offic
certain procedur done out-of-pocket cost could view substanti
peopl unemploy worri becom unemploy howev econom
trend overal employ improv medical-surg distribut busi could improv
incom statement model fiscal year end june
million
good sold
total revenu
total revenu
sale carefus stock
loss debt extinguish
weight average number share
incom statement model fiscal year end june
million
margin expans bp
margin expans bp
